Diane Healey

6.5k total citations
33 papers, 1.4k citations indexed

About

Diane Healey is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Diane Healey has authored 33 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 8 papers in Molecular Biology. Recurrent topics in Diane Healey's work include Cancer Immunotherapy and Biomarkers (15 papers), Peptidase Inhibition and Analysis (9 papers) and Chronic Lymphocytic Leukemia Research (5 papers). Diane Healey is often cited by papers focused on Cancer Immunotherapy and Biomarkers (15 papers), Peptidase Inhibition and Analysis (9 papers) and Chronic Lymphocytic Leukemia Research (5 papers). Diane Healey collaborates with scholars based in United States, Italy and Germany. Diane Healey's co-authors include Nicole Onetto, Mansoor N. Saleh, Bo Huang, Andreas Hochhaus, Giuseppe Saglio, Jörge E. Cortes, Hesham Mohamed, Charles A. Schiffer, Hagop M. Kantarjian and Anthony W. Tolcher and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Diane Healey

33 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Diane Healey United States 15 931 335 308 292 289 33 1.4k
Dominic Fong Austria 21 916 1.0× 241 0.7× 239 0.8× 179 0.6× 117 0.4× 33 1.7k
Hidekazu Segawa Japan 15 458 0.5× 106 0.3× 175 0.6× 180 0.6× 233 0.8× 20 985
Martin Kornacker Germany 20 564 0.6× 399 1.2× 160 0.5× 123 0.4× 138 0.5× 59 1.3k
Anna Novarino Italy 19 577 0.6× 319 1.0× 111 0.4× 80 0.3× 197 0.7× 43 1.1k
M. Luisa Paccagnella United States 13 857 0.9× 123 0.4× 275 0.9× 152 0.5× 439 1.5× 22 1.7k
Becker Hewes United States 18 1000 1.1× 624 1.9× 393 1.3× 65 0.2× 216 0.7× 34 2.0k
Susanna Cappia Italy 24 766 0.8× 293 0.9× 748 2.4× 91 0.3× 120 0.4× 56 2.0k
Rodrigo Ruiz‐Soto United States 16 438 0.5× 169 0.5× 544 1.8× 178 0.6× 63 0.2× 61 1.3k
Martin D. Phillips United States 12 349 0.4× 144 0.4× 275 0.9× 98 0.3× 192 0.7× 16 978
Ivan Inigo United States 10 363 0.4× 160 0.5× 110 0.4× 90 0.3× 146 0.5× 21 693

Countries citing papers authored by Diane Healey

Since Specialization
Citations

This map shows the geographic impact of Diane Healey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Diane Healey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Diane Healey more than expected).

Fields of papers citing papers by Diane Healey

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Diane Healey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Diane Healey. The network helps show where Diane Healey may publish in the future.

Co-authorship network of co-authors of Diane Healey

This figure shows the co-authorship network connecting the top 25 collaborators of Diane Healey. A scholar is included among the top collaborators of Diane Healey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Diane Healey. Diane Healey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Tsimberidou, Apostolia M., Veronica R. Holley, Sapna P. Patel, et al.. (2021). Targeting innate immunity with BXCL701 in combination with pembrolizumab in patients with advanced solid cancers: Phase 2 basket study.. Journal of Clinical Oncology. 39(15_suppl). 2558–2558. 2 indexed citations
3.
Aggarwal, Rahul, Dan Costin, Jingsong Zhang, et al.. (2021). BXCL701, first-in-class oral activator of systemic innate immunity pathway, combined with pembrolizumab (Keytruda) in men with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 39(6_suppl). 124–124. 4 indexed citations
4.
Aggarwal, Rahul, Dan Costin, Vincent O’Neill, et al.. (2020). Safety of BXCL701, a small molecule inhibitor of dipeptidyl peptidases (DPP), with pembrolizumab, (pembro, anti-PD-1) monoclonal antibody, in men with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 38(6_suppl). 140–140. 1 indexed citations
5.
Aggarwal, Rahul, Dan Costin, Vincent O’Neill, et al.. (2020). Phase 1b study of BXCL701, a novel small molecule inhibitor of dipeptidyl peptidases (DPP), combined with pembrolizumab (pembro), in men with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 38(15_suppl). e17581–e17581. 6 indexed citations
6.
Peters, Solange, Federico Cappuzzo, Leora Horn, et al.. (2017). OA03.05 Analysis of Early Survival in Patients with Advanced Non-Squamous NSCLC Treated with Nivolumab vs Docetaxel in CheckMate 057. Journal of Thoracic Oncology. 12(1). S253–S253. 37 indexed citations
7.
Font, E. Felip, Scott Gettinger, Scott Antonia, et al.. (2017). Three-year follow-up from CheckMate 017/057: Nivolumab versus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC). Annals of Oncology. 28. v462–v462. 22 indexed citations
8.
Barlési, Fabrice, Martin Steins, Leora Horn, et al.. (2016). Long-term outcomes with nivolumab (Nivo) vs docetaxel (Doc) in patients (Pts) with advanced (Adv) NSCLC: CheckMate 017 and CheckMate 057 2-y update. Annals of Oncology. 27. vi420–vi420. 16 indexed citations
9.
Borghaei, Hossein, Julie R. Brahmer, Leora Horn, et al.. (2016). Nivolumab (nivo) vs docetaxel (doc) in patients (pts) with advanced NSCLC: CheckMate 017/057 2-y update and exploratory cytokine profile analyses.. Journal of Clinical Oncology. 34(15_suppl). 9025–9025. 27 indexed citations
10.
Reshmi, Shalini C., Eileen Stonerock, Michael J. Borowitz, et al.. (2015). International Laboratory Comparison of Methodologies for Determining Minimal Residual Disease (MRD) in Childhood Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL). Blood. 126(23). 2612–2612. 2 indexed citations
11.
Shah, Neil P., François Guilhot, Jörge E. Cortes, et al.. (2014). Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study. Blood. 123(15). 2317–2324. 140 indexed citations
12.
Shah, Neil P., Hagop M. Kantarjian, Dong‐Wook Kim, et al.. (2012). Six-year (yr) follow-up of patients (pts) with imatinib-resistant or -intolerant chronic-phase chronic myeloid leukemia (CML-CP) receiving dasatinib.. Journal of Clinical Oncology. 30(15_suppl). 6506–6506. 31 indexed citations
13.
Healey, Diane, Petteri Carlson, Bin Huang, & Margaret Marshall. (2010). Clinical outcome of first-line melanoma patients who continue tremelimumab in spite of early disease progression.. Journal of Clinical Oncology. 28(15_suppl). 2574–2574. 4 indexed citations
14.
Rini, Brian I., Mark N. Stein, Simantini Eddy, et al.. (2010). Phase 1 dose‐escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma. Cancer. 117(4). 758–767. 119 indexed citations
15.
Chung, Ki Y., Ira Gore, Lawrence Fong, et al.. (2010). Phase II Study of the Anti-Cytotoxic T-Lymphocyte–Associated Antigen 4 Monoclonal Antibody, Tremelimumab, in Patients With Refractory Metastatic Colorectal Cancer. Journal of Clinical Oncology. 28(21). 3485–3490. 238 indexed citations
16.
17.
Gordon, Michael, Mark N. Stein, Simantini Eddy, et al.. (2009). Phase I dose escalation trial of tremelimumab plus sunitinib in patients (pts) with metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology. 27(15_suppl). 5115–5115. 6 indexed citations
18.
Bulanhagui, C. A., Prudence Dorazio, Diane Healey, et al.. (2008). Safety of tremelimumab (CP-675,206) in patients (pts) with advanced cancer. Journal of Clinical Oncology. 26(15_suppl). 3040–3040. 8 indexed citations
19.
Tolcher, A. W., James J. O’Leary, Johann S. de Bono, et al.. (2004). 137 A phase I study of an oral vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor, CP-547,632, in patients with advanced solid tumors. European Journal of Cancer Supplements. 2(8). 44–44. 7 indexed citations
20.
Gelmon, Karen A., Sean OʼReilly, Anthony W. Tolcher, et al.. (1996). Phase I/II trial of biweekly paclitaxel and cisplatin in the treatment of metastatic breast cancer.. Journal of Clinical Oncology. 14(4). 1185–1191. 54 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Dominic Fong Breakdown of academic impact, for papers by Hidekazu Segawa Breakdown of academic impact, for papers by Martin Kornacker Breakdown of academic impact, for papers by Anna Novarino Breakdown of academic impact, for papers by M. Luisa Paccagnella Breakdown of academic impact, for papers by Becker Hewes Breakdown of academic impact, for papers by Susanna Cappia Breakdown of academic impact, for papers by Rodrigo Ruiz‐Soto Breakdown of academic impact, for papers by Martin D. Phillips Breakdown of academic impact, for papers by Ivan Inigo
Rankless by CCL
2026